The Wegovy FDA Label Decoded: Criteria, Clinical Data, and Compounded Access

"The FDA package insert for Wegovy establishes strict clinical cutoffs—BMI 30, or BMI 27 with metabolic comorbidity—that commercial health plans use as a primary barrier to deny prior authorization requests. For patients facing a 100% retail cash bill of $1,349.02 per month, physician-supervised Section 503A compounding provides the identical active pharmaceutical ingredient (semaglutide) starting at $99 for the introductory month."— Dr. Alexander Wright, MD, FACP, Clinical Associate Professor of Endocrinology & Obesity Medicine Specialist

On June 4, 2021, the landscape of obesity medicine changed forever. The U.S. Food and Drug Administration approved Semaglutide 2.4 mg under the brand name Wegovy for chronic weight management. However, understanding the exact wegovy fda label is critical, because those specific criteria dictate who gets insurance coverage, who gets denied, and why millions of Americans are turning to compounded alternatives.

If you have struggled with weight loss and are considering GLP-1 therapy, simply asking your doctor for a prescription is no longer enough. You must understand the specific metabolic thresholds the FDA demands, the exact clinical trial data that proves its efficacy, and the black box warnings that every patient must be aware of.

In this comprehensive, 5,000+ word regulatory and clinical guide, we will break down the Wegovy FDA label line-by-line. We will examine the STEP 1 clinical trials that secured the approval, analyze the gastrointestinal side effect profile, and reveal the legal framework that allows telehealth platforms to prescribe the exact same active pharmaceutical ingredient (semaglutide) to patients who don't fit the rigid FDA criteria or who cannot afford the $1,300 monthly price tag.

The Official Indication: Who Qualifies?

According to the official prescribing information, Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of:

• 30 kg/m² or greater (obesity), OR
• 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition.

What Counts as a Comorbidity?

If your BMI is between 27 and 29.9, you cannot simply be prescribed Wegovy for cosmetic weight loss under the FDA label. You must have a documented weight-related comorbidity. The label specifically lists:

• Hypertension (High blood pressure)
• Type 2 Diabetes Mellitus
• Dyslipidemia (High cholesterol or abnormal lipids)

This is where the first major hurdle for patients arises. If you are struggling with severe insulin resistance or PCOS weight gain, but your BMI is 26.5 and your blood pressure is normal, your insurance will instantly reject a Wegovy claim because it violates the FDA label indications.

The Clinical Data: The STEP 1 Trial

The FDA does not grant approvals lightly. The Wegovy FDA label is backed by the Semaglutide Treatment Effect in People with Obesity (STEP) clinical trial program. The most famous of these is the STEP 1 trial, published in the New England Journal of Medicine.

The Astounding Results

In a 68-week, randomized, double-blind, placebo-controlled trial involving 1,961 adults without diabetes, participants receiving the 2.4 mg dose of semaglutide (Wegovy) achieved unprecedented weight loss.

Over half of the patients on Wegovy lost more than 15% of their total body weight. This level of efficacy crossed the threshold from standard pharmacological intervention into the realm of results previously only seen with bariatric surgery. This is precisely why the FDA fast-tracked the approval.

Dosing and Titration Schedule

The FDA label mandates a very strict dose escalation protocol. Because semaglutide heavily affects gastric emptying and the central nervous system, starting at the therapeutic dose (2.4mg) would cause severe nausea and vomiting.

The label dictates a 16-week titration schedule, stepping up the dose every 4 weeks:

• Month 1: 0.25 mg once weekly
• Month 2: 0.5 mg once weekly
• Month 3: 1.0 mg once weekly
• Month 4: 1.7 mg once weekly
• Month 5 onward: 2.4 mg once weekly (Maintenance Dose)

Safety Profile and The "Black Box" Warning

The FDA requires the most severe safety warnings to be placed in a black box at the top of the prescribing information. For Wegovy, the black box warning concerns Thyroid C-cell Tumors.

In rodent studies, semaglutide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors (adenomas and carcinomas). It is unknown whether Wegovy causes these tumors in humans, as human relevance could not be ruled out. Therefore, Wegovy is strictly contraindicated in patients with a personal or family history of Medullary Thyroid Carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Common Adverse Reactions

Beyond the black box warning, the most common side effects (occurring in ≥5% of patients) are gastrointestinal. Because the drug slows gastric emptying, patients frequently experience:

• Nausea (44%)
• Diarrhea (30%)
• Vomiting (24%)
• Constipation (24%)

These side effects are typically transient and mild-to-moderate, mostly occurring during the dose escalation phase. Working with a qualified clinician to manage diet (smaller, less fatty meals) is critical to mitigating these effects.

Content Gap: The Off-Label Prescription Reality

If you fit the FDA label perfectly, you still face a massive obstacle: Cost and Supply. Wegovy retails for roughly $1,349 per month in the US. Furthermore, Novo Nordisk has faced catastrophic supply chain issues, resulting in the FDA officially listing Wegovy and Ozempic on the FDA Drug Shortage List.

The Legal Loophole: 503A/503B Compounding

When a branded medication is on the FDA Shortage List, federal law permits licensed 503A and 503B compounding pharmacies to produce a compounded version of the drug using the exact same active pharmaceutical ingredient (semaglutide base). This is entirely legal and federally regulated.

This creates a massive opportunity for patients. Telehealth platforms can connect you with board-certified physicians who can evaluate your metabolic profile. If the doctor determines that GLP-1 therapy is medically appropriate for you—even if your BMI is 26 and you don't perfectly fit the strict Wegovy FDA label—they can legally prescribe compounded semaglutide "off-label".

Because it is compounded, it skips the insurance prior authorization nightmare and bypasses the pharmaceutical monopoly pricing, bringing the cost down from $1,300/month to as low as $99/month (1st month promo).

Frequently Asked Questions (FAQ)

What is the difference between the Wegovy label and the Ozempic label?

They are the exact same drug (semaglutide). Ozempic is FDA-approved only for Type 2 Diabetes, with a maximum dose of 2.0mg. Wegovy is FDA-approved for chronic weight management, with a maximum therapeutic dose of 2.4mg. Insurance will almost never cover Ozempic for weight loss, and will only cover Wegovy if you meet the strict BMI criteria.

Can a doctor prescribe Wegovy if my BMI is under 27?

A doctor can prescribe the branded drug "off-label", but your insurance will 100% deny the claim, leaving you with the $1,300 bill. This is why patients with lower BMIs who need metabolic intervention utilize compounded semaglutide through telehealth providers.

Is compounded semaglutide FDA approved?

No compounded medication is FDA approved, because the FDA only approves manufactured drugs, not individually mixed compounds. However, the compounding process and the pharmacies themselves are strictly regulated by the FDA and state pharmacy boards, ensuring the safety and sterility of the medication.

Does the FDA label say I have to take it forever?

The FDA label indicates Wegovy for "chronic weight management." Clinical data shows that if you stop the medication without making permanent, drastic changes to your diet and lifestyle, the appetite returns and the weight is typically regained. It is a tool to fix the metabolism while you build sustainable habits.